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Abstract: BACKGROUND Lymphoedema is a progressive and potentially disabling disease. A grow-
ing number of studies show promising clinical results after microsurgical reconstruction. However, this
treatment is currently not supported by level 1 evidence and insurance coverage is variable. METHODS
Electronic records of 55 patients with limb lymphoedema, who were eligible for lymphovenous bypass
surgery and/or lymphatic tissue transfer in our department from 2017 to 2020, were reviewed. Corre-
spondence between our department and health insurers was analysed. A web-based search and individual
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was 1.3 plusmn; 0.7. The time between confirmation of the indication and the final decision ranged from
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the individual insurance company. No insurance company had policies publicly available online and all
stated that they determine coverage only when provided with specific patient details on a case-by-case
basis. CONCLUSION Insurance companies in Switzerland do not have a uniform policy regarding cost
coverage for lymphatic surgery procedures. Moreover, the decision process appeared to be rather uniform
within the respective insurance company and independent of the individual case. Standardised evaluation
criteria including patient reported outcome measures should be developed to underscore the beneficial
effects of lymphatic surgery and facilitate insurance coverage.
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Summary
BACKGROUND: Lymphoedema is a progressive and po-
tentially disabling disease. A growing number of studies
show promising clinical results after microsurgical recon-
struction. However, this treatment is currently not support-
ed by level 1 evidence and insurance coverage is variable.
METHODS: Electronic records of 55 patients with limb
lymphoedema, who were eligible for lymphovenous by-
pass surgery and/or lymphatic tissue transfer in our de-
partment from 2017 to 2020, were reviewed. Correspon-
dence between our department and health insurers was
analysed. A web-based search and individual telephone
interviews were conducted to identify health insurer poli-
cies.
RESULTS: We included 42 patients undergoing 46 opera-
tions and evaluated the correspondence between our de-
partment and nine different health insurers. Overall, reim-
bursement of costs was approved in 67% (n = 31) of all
surgeries and was refused in 33% (n = 15). The mean
number of applications for reconsideration sent to insurers
was 1.3 ± 0.7. The time between confirmation of the in-
dication and the final decision ranged from 6 to 300 days
(mean 50 days). Reimbursement of cost coverage ranged
from 0% to 100% depending on the individual insurance
company. No insurance company had policies publicly
available online and all stated that they determine cover-
age only when provided with specific patient details on a
case-by-case basis.
CONCLUSION: Insurance companies in Switzerland do
not have a uniform policy regarding cost coverage for
lymphatic surgery procedures. Moreover, the decision
process appeared to be rather uniform within the respec-
tive insurance company and independent of the individual
case. Standardised evaluation criteria including patient re-
ported outcome measures should be developed to under-
score the beneficial effects of lymphatic surgery and facili-
tate insurance coverage.
Introduction
Lymphoedema is a progressive and potentially debilitating
condition of chronic localised retention of protein-rich in-
terstitial fluid and tissue remodelling caused by a com-
promised lymphatic system, which can be hereditary (pri-
mary) or acquired (secondary) [1]. The condition can be
disabling psychologically and physically. Negative effects
brought on by the impairment of activities in daily life
and reduced limb aesthetics decrease health-related quality
of life [2–5]. In developed countries, lymphoedema most
commonly occurs after cancer treatment. Symptoms in-
clude swelling, recurrent skin infections and impairment
of limb functionality. Complex physical therapy represents
the gold standard for basic treatment of symptomatic lym-
phoedema. It is very often effective, yet often needs to be
applied life-long because it does not treat the underlying
causes and includes general skin care [6, 7].
A growing amount of literature reports promising clinical
outcomes in lymphoedema patients following microsurgi-
cal reconstruction [8–14]. Two surgical concepts are cur-
rently employed: bypassing lymphatic fluid by anastomos-
ing congested lymph vessels to venules (lymphovenous
anastomosis, LVA) or microvascular transfer of lymphatic
tissue to the affected limb (LTT). These options can per-
formed either sequentially or singly, depending on lym-
phoedema stage and postsurgical outcomes. Especially in
early stages of lymphoedema, where lymphatic vessels are
not yet fibrotic, the outcome after LVA is promising. It rep-
resents a reconstructive procedure. Its combination with
LTT might potentially improve overall results, but this has
yet to be proven.
Surgical treatment is currently not supported by level 1 ev-
idence. In 2018, researchers from the Ludwig-Boltzmann
Institute in Austria conducted a systematic review on the
effectiveness of LVA in lymphoedema and published a na-
tional decision support document [15]. Owing to method-
ological shortcomings, they could not conclude whether
the LVA is at least equally effective and safer than the com-
parator LTT or conservative treatment, and back then ini-
tially recommended a temporary withholding of cost re-
imbursement. However, after several communications with
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the Austrian Health Insurance Fund, LVA and LTT were
finally listed as novel surgical therapies in the 2020 reim-
bursement catalogue [16].
Insurance companies in Switzerland still use an individ-
ualised approach to cost coverage of lymphatic micro-
surgery. The use of lymphatic reconstructive surgery for
the treatment of lymphoedema is not generally reimbursed
by the Swiss healthcare system at this point of time. A
written request is needed in all cases. And some insurers
cover lymphatic microsurgery after receiving a written re-
quest. How such policies play out in practice is important
for patients and providers as there is often a discordance
between the coverage criteria determined by insurers and
indications for the procedures recognised by plastic sur-
geons. In order to contribute to the understanding of this
situation in Switzerland, we reviewed insurance coverage
policies and coverage decisions from 2017 to 2020 in our
institution.
Materials and methods
At the University Hospital in Zurich we have established a
registry to follow up all lymphoedema patients who have
been treated with lymphatic microsurgery since September
2016, for internal qualitative analysis (KEK ID
Req-2018-00284). Approval to conduct this retrospective
analysis was additionally obtained from the local insti-
tutional review board (KEK BASEC ID 2019-00947) in
2019.
This institutional experience is from the University Hospi-
tal of the Canton Zurich with the biggest catchment area.
Although most probably representative for Switzerland,
outcomes in Zurich may not be valid for every single can-
ton or local healthcare system in Switzerland. However,
currently surgeons offering lymphatic surgery cannot take
reimbursement for granted and this is observed all over
Switzerland. At our department we routinely file a written
application for reimbursement of costs to health insurers
prior to the planned surgery.
Diagnosis and eligibility for treatment
Diagnosis of lymphoedema is generally based on patient
history, clinical examination and subjective symptoms,
with testing used to rule out other potential causes and
confounding conditions. The International Society of Lym-
phology (ISL) Staging System is applied to further classify
lymphedema. Imaging modalities are useful adjuncts to the
ISL staging to clarify the diagnosis. At our institution, lym-
phoedema patients who are assigned for surgical therapy
are discussed in an interdisciplinary setting by an angiol-
ogist, plastic surgeon and physiotherapist. This multidisci-
plinary group reviews all patients regardless of insurance
status or financial capacities. Eligible patients were those
judged medically appropriate for reconstructive microsur-
gical therapies. No patient received reconstructive treat-
ment without previous complex decongestive therapy over
at least 6 months by experienced physiotherapists.
Patient selection algorithm for treatment
Patients receive treatment according to the disease stage
and their general condition in a standardised institutional
approach. Patients who have had lymphoedema for 3 years
and with lymphoedema stage I–II usually have little fibro-
sis and functional lymphatics. LVA is then performed to
prevent progression of the disease and treat already exist-
ing lymphoedema. In patients who have had lymphoedema
for more than 3 years, in stage II–III and in patients with
primary lymphoedema, lymphatics are often sclerotic, non-
functional or absent. These patients qualify for LTT. How-
ever, intraoperative impedance cardiography-guided LVA
is usually attempted in order to facilitate more rapid decon-
gestion, especially in the distal part of the limb. Suction-
assisted lipectomy may be useful both as a primary and
secondary “touch-up” procedure in lymphoedema stage
II–III patients after lymphatic reconstruction. Excisional
debulking procedures should be limited to morbid stage IV
lymphoedema cases (elephantiasis). Surgery is performed
under general anaesthesia for better patient comfort and
patients are hospitalised for two to four nights. A standard
protocol requires postoperative follow-up of all patients to-
gether with the physiotherapist in our outpatient clinic at
2 weeks, 6 weeks, 3 months and 1 year postoperatively.
Physiotherapy including compression garments, bandages
and manual lymphatic drainage is initiated gradually at 2
weeks postoperatively. Limb measurements are taken by
the physiotherapist at every visit.
Data extraction
Patients’ electronic records were reviewed and correspon-
dence between our department and the health insurers be-
tween 2017 and 2020 were analysed. We excluded interna-
tional patients, cases with incomplete records, and patients
who refused approval for data evaluation. A list of ratio-
nales and explanations was abstracted from the correspon-
dence. Number of communications and time between con-
firmation of the indication by the plastic surgeon and the
final decision on the assumption of costs from health in-
surers were reviewed. Further demographic data, insurance
details and outcomes after application for reimbursement
of costs were extracted from the patient chart.
A web-based search aimed at identifying whether estab-
lished medical criteria and policies were publicly acces-
sible on the corresponding company’s website. When the
policy could not be abstracted from the company website,
a telephone call was made. We aimed to assess individual
criteria for the decisions. The insurance company was
deemed to not have a policy for reconstructive micro-
surgery surgery in lymphoedema patients only if con-
firmed by a representative of the company.
Data analysis
The statistical analysis used descriptive and summary sta-
tistics to identify central tendencies. Data were analysed
using Microsoft® Excel Version 14.3.6. (Microsoft Corp.,
Redmond, WA, USA). Continuous variables are expressed
as mean ± standard deviation. Categorical variables are
expressed as frequencies or percentages. This study was
conducted according to the STROBE (Strengthening the
Reporting of Observational studies in Epidemiology)
guidelines.
Results
We reviewed 55 patient charts and included 42 patients
who were eligible for analysis. They had either already
undergone or were scheduled for lymphatic microsurgery.
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Four patients underwent two subsequent lymphatic recon-
structive surgeries. Finally, a total of 46 sets of corre-
spondence between our department and the insurance com-
panies were identified. Thirteen patients were excluded
because of incomplete records, lack of or refusal to sign the
institutional general consent form, or because they were in-
ternational patients. Figure 1 shows a flow chart for patient
selection.
Thirty-eight patients were female (90%) and four patients
were male (10%). The age of the patients ranged from 21
to 77 years (mean ± standard deviation 52 ± 11). Mean
body mass index (BMI) was 27 ± 5 kg/m2. Seven patients
had primary lymphoedema and had developed lymphoede-
ma in adulthood: The disease occurred at an average age of
41 years (range 26–61). One patient had a family history of
lymphoedema. Secondary lymphoedema was present in 35
patients for more than 3 years. Lower limb lymphoedema
was present in 33 patients and upper limb lymphedema in 9
patients. Seventeen patients had ISL stage I lymphoedema,
22 patients stage II and 3 patients stage III. Ten surgeries
were scheduled and a total of 36 surgeries had already been
performed. We performed multiple LVA in 22 patients, of
whom 3 underwent LTT sequentially (i.e., in a second op-
eration following the LVA procedure) and 1 had a second
LVA procedure. One patient received LTT only. Nine pa-
tients had LVA and LTT simultaneously in one operation
and for 10 patients for this combined surgical approach
was planned. Main subjective improvements reported by
patients at 6 months postoperatively were: less pressure
sensation, less tension, increased softness, less heaviness,
reduced swelling, increased mobility and pain reduction.
Table 1 details demographic data for each procedure, dis-
tribution of the patients concerning stage of lymphoedema,
insurance details and outcomes after application for reim-
bursement of costs for each surgical case. The distribution
of patients’ BMI was comparable between the different in-
surance companies.
A written application for cost coverage from health insur-
ers was required at all times. The following additional in-
formation was requested in all cases if missing: discharge
letter from a rehabilitation centre or further evidence and
results of physiotherapy, clinical pictures, and assessment
by an angiologist. Lymphoscintigraphy was requested in
only two primary and three secondary stage II lymphoede-
ma cases. In 31 of 46, cases insurers requested an addi-
tional approval by an independent medical examiner. All
refused cases had been previously assessed by an indepen-
dent medical examiner (Vertrauensarzt). Reimbursement
of costs was approved in 67% (n = 31) of all surgeries and
was refused in 33% (n = 15). The mean number of appli-
cations for reconsideration sent to insurers was 1.3 ± 0.7.
Figure 1: Patient and case selection.
The time between confirmation of the indication and final
decision ranged from 6 to 300 days (mean 50 days). Main
reasons for refusal are listed in table 2. In 4 of 15 finally re-
fused requests, health insurers recommended continuation
of physiotherapy for patients with ISL stage I lymphoede-
ma due to beneficial results of complex decongestive ther-
apy. Five patients with refused reimbursement appeals had
received private physiotherapy for 6 months but had not
had complex decongestive therapy in a specialised clinic
for management of peripheral lymphoedema. Reimburse-
ment of costs was refused for 3 of 4 ISL stage III and 4
of 25 ISL stage II lymphoedema surgery cases. Reimburse-
ment was approved by insurers in 88% (7 of 8 cases) of
primary lymphoedema cases and 66% (25 of 38) of all sec-
ondary lymphoedema cases.
We identified nine different insurance companies, which
were given letters from A to I for differentiation. Figure
2 shows the total number of requests and number of re-
fused requests for reimbursement per health insurers A–I.
Numbers in percentages represent the overall reimburse-
ment rate. We noticed that some insurers such as insurer C
approved all requests for reimbursement of costs whereas
others such as insurer E declined most requests. When we
compared patient characteristics, similarities or analogies
in decision making among insurers could not be identified.
No insurance company had clearly defined policies regard-
ing coverage of the respective procedures publicly avail-
able online. All gave telephone interviews. No insurance
company was able to provide established policies or spec-
ify medical necessity criteria for cost coverage. However,
all nine companies assured us that they determined cov-
erage for reconstructive lymphatic microsurgery in lym-
phoedema patients on a case-by-case basis. The final de-
cision is usually made based on the assessment by an
independent medical examiner. Figure 3 depicts the finally
approved and refused requests for reimbursement per year
from 2017–2020 in total numbers and percentages. In 2020
(the first 6 months) most of our requests were approved.
Discussion
There are few data evaluating insurance approval for lym-
phoedema treatment by reconstructive microsurgery. The
field of super/microsurgical reconstructive procedures for
lymphoedema is rapidly expanding. Technology is pro-
gressing, together with solid clinical experience, and skills
as well as tools have qualitatively improved since the first
experimental implementation in 1960 [17]. The need for
requesting reimbursement by the insurance company for
non-cosmetic surgery seems to be specific to the healthcare
systems that utilise the diagnosis-related groups (DRG)
system or DRG-like systems, which are intended to identi-
fy the “products” that a hospital provides. This is the case
in Switzerland, Germany and Austria, whereas some oth-
er European countries manage this issue very differently
(e.g., France and Italy: securité sociale). It is difficult for
patients and providers to accept that some patients are able
to receive insurance coverage for these surgical procedures
and some do not. We have examined outcomes of appli-
cations for reimbursement of costs of microsurgical recon-
structive therapies in lymphoedema patients in our unit.
According to the guidelines of the German Association of
Scientific Medical Societies (AWMF) from May 2017, sur-
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gical therapy for lymphoedema should then be considered
whenever tissue changes aggravate under complex decon-
gestive therapy and patients continue to suffer greatly from
the disease [18]. These consensus guidelines are expect-
ed to be reviewed and adapted to the current level of ev-
idence and clinical practice in the near future. With the
Table 1: Demographic data, insurance details and outcomes per surgical case.
ID Type of lymphoedema ISL stage
(1–3)









1 Secondary 2 Arm F 2017 LVA A 1 Approve
2 Primary 2 Leg F 2018 LVA B 1 Approve
3 Primary 2 Leg F 2017 LVA B 1 Approve
4 Secondary 1 Arm F 2018 LVA B 1 Refuse
5 Primary 2 Leg F 2019 LTT B 1 Approve
6 Secondary 2 Leg F 2020 LVA and LTT B 1 Approve
7 Secondary 1 Arm F 2020 LVA B 1 Approve
8 Secondary 2 Leg F 2020 LVA and LTT B 1 Approve
9 Secondary 1 Leg F 2018 LVA B 1 Approve
10 Secondary 2 Leg F 2018 LTT C 1 Approve
11 Secondary 1 Leg F 2018 LVA C 1 Approve
12 Secondary 1 Leg F 2019 LVA C 1 Approve
13 Primary 1 Leg F 2017 LVA C 1 Approve
14 Secondary 2 Leg F 2020 LVA and LTT C 1 Approve
15 Secondary 2 Leg F 2020 LVA and LTT C 1 Approve
16 Secondary 1 Arm F 2019 LVA C 1 Approve
17 Primary 2 Leg F 2019 LVA and LTT C 1 Approve
18 Secondary 2 Leg F 2020 LVA and LTT C 1 Approve
19 Secondary 2 Arm F 2020 LVA and LTT C 1 Approve
20 Secondary 2 Leg M 2020 LVA and LTT C 1 Approve
21 Secondary 2 Leg F 2017 LVA D 1 Approve
22 Secondary 3 Leg F 2019 LVA and LTT E 3 Refuse
23 Secondary 1 Leg F 2019 LVA and LTT E 2 Refuse
24 Secondary 1 Leg F 2019 LTT E 1 Refuse
25 Secondary 2 Leg F 2018 LVA E 1 Approve
26 Secondary 3 Arm F 2017 LTT E 1 Refuse
27 Secondary 1 Leg F 2017 LVA E 3 Refuse
28 Secondary 2 Leg M 2017 LVA E 1 Approve
29 Secondary 1 Arm F 2017 LVA E 2 Refuse
30 Secondary 1 Leg F 2017 LVA E 2 Refuse
31 Secondary 3 Arm F 2017 LVA E 2 Refuse
32 Secondary 1 Leg F 2017 LVA F 1 Approve
33 Secondary 1 Leg F 2018 LVA F 1 Approve
34 Secondary 2 Leg F 2018 LVA F 1 Approve
35 Secondary 2 Leg F 2019 LVA F 1 Approve
36 Secondary 1 Arm F 2019 LVA and LTT F 1 Approve
37 Primary 1 Leg F 2019 LVA and LTT F 2 Refuse
38 Secondary 3 Leg M 2020 LVA and LTT F 1 Approve
39 Primary 2 Leg F 2020 LVA and LTT F 1 Approve
30 Secondary 2 Leg F 2020 LVA and LTT G 1 Refuse
41 Secondary 2 Leg F 2020 LVA and LTT G 1 Refuse
42 Primary 2 Leg M 2017 LVA G 1 Approve
43 Secondary 2 Arm F 2020 LVA and LTT H 2 Approve
44 Secondary 1 Leg F 2018 LVA H 3 Refuse
45 Secondary 2 Leg F 2020 LVA and LTT I 2 Refuse
46 Secondary 2 Leg F 2020 LVA and LTT I 4 Refuse
F = female; ID = patient number; ISL = International Society of Lymphoedema; LTT = lymphatic tissue transfer; LVA = lymphovenous anastomosis; M = male
Table 2: Main reasons for refusal to reimburse lymphatic microsurgery costs in lymphoedema patients.
Reason for refusal Number of cases
Complete decongestive therapy seems to be beneficial solely. Continuation is recommended. 4
Complete decongestive therapy for 6 months is a prerequisite. 5
Method is not sufficiently established. 14
Level 1 evidence is not available. 13
Long-term results not available. 12
Treatments are considered as experimental. 13
Efficacy and profitability are not proven. 14
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intent to improve the level of standardisation for further
multicentre studies in the field of lymphoedema treatment
in the German speaking countries, a consensus paper of
the German-Speaking Society for Microsurgery of Periph-
eral Nerves and Vessels (DAM) on indication, diagnostic
and therapy with lymphovenous anastomosis (LVA) and
vascularised lymph node transfer (LTT) was published in
November 2019 [19]. The group reviewed 27 studies with
a total of 1619 patients over a time period of 3.3 years
and found that the reduction in size was approximately
the same for both procedures (LVA vs vascularised lymph
node transfer) and was around 48%. They also found that
LTT was more efficient in volume reduction if patients
stopped complex decongestive therapy postoperatively and
that treatment resulted in a significant subjective improve-
ment in the quality of life of patients [19]. Patients in early
lymphoedema stages are most likely to benefit from LVA
as the lymphatics are less prone to lymph stasis and have
not yet undergone major structural changes such as fibro-
sis or sclerosis. Thus, the technical quality of LVA will
increase. LTT may have long-term effects and may be of
benefit in late stage lymphoedema where the lymphatics
do not have enough transport capacity as a result of the
aforementioned structural changes. A combination of both
procedures is currently being used by only a few surgeons.
The transferred lymphatic tissue may generate new lym-
phatic pathways and stabilise the disease or accelerate the
LVA outcomes and the other way around. The preoperative
Figure 2: Total number of requests (blue) and refused requests (orange) for reimbursement per health insurer A–I. Reimbursement rates are
given in percentages.
Figure 3: Final decisions per year from 2017–2020. * Includes the first 6 months only.
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evaluation presented in this article differs from the consen-
sus of the German-Speaking Society for Microsurgery of
Peripheral Nerves and Vessels (DAM) on indication, di-
agnosis and therapy by LVA and vascularised lymph node
transfer, which was developed over the study period. In
general, we have followed most of the recommendations
of the consensus paper with only minor institutional dif-
ferences. Additionally, it is very likely that these recom-
mendation on indication, diagnosis and therapy of lym-
phoedema are subject to change once more standardised
procedures are used and larger scale data including long-
term outcomes are available.
In the meantime, in Germany LTT can be carried out with-
out consulting the health insurance companies beforehand
and is a recognised therapy.
In another attempt to publish a national decision-support
document for insurers, researchers from the Ludwig-Boltz-
mann Institute in Austria conducted a systematic review
on the effectiveness of LVA in lymphoedema in 2018 [15].
They identified one non-randomised controlled study with
a total of 43 patients, which assessed the effectiveness of
LVA compared with vascularised supraclavicular lymph
node transfer in 13 patients, in order to assess the safety
and efficacy of the treatment. On the basis of the available
evidence and because of methodological shortcomings,
they could not conclude whether the assessed procedure
LVA is at least equally effective and safer than the com-
parator LTT or conservative treatment. In 2018, they ini-
tially recommended a temporary withdrawal of reimburse-
ment for lymphatic microsurgery in Austria. Recently,
Tzou et al. shared their Austrian experience on how to es-
tablish a lymphoedema centre in Europe [16]. In Austria,
because of differences in governmental healthcare reim-
bursement, no mandate is needed for applications for reim-
bursement for a new surgical lymphoedema therapy [16].
Their first application for reimbursement in 2018 was re-
jected, but the next one, in 2019, was approved by the Aus-
trian Health Insurance Fund for listing as novel surgical
therapy in its 2020 catalogue. They claim that introduc-
ing a new procedure for lymphoedema surgery was like in-
troducing a new brand onto the market and that informa-
tion played an important role for patients and referrals [16].
They added that the evaluation of lymphoedema patients’
perceptions, requirements of the surgical setup, and insur-
ance conditions for lymphoedema surgery are essential to
support managerial decisions to promote and institution-
alise lymphedema surgery, thereby providing better access
for lymphoedema patients to this treatment [16].
In Switzerland the Department of Internal Affairs (Eid-
genössisches Departement des Inneren, EDI), represented
by the Federal Office of Public Health (BAG), is respon-
sible for the management of a “service catalogue” of the
compulsory health insurance (OKP) in accordance with the
Swiss health insurance act (Krankenversicherungsgesetz,
KVG) [20]. However, this provides not an explicit cata-
logue or general scope of services, but rather a categori-
sation of services that are published as the Health Care
Benefits Ordinance (Krankenpflege-Leistungsverordnung,
KLV). New treatments therefore require a written request
for reimbursement of costs in Switzerland and insurers
may ask for an assessment by an independent medical ex-
aminer (Vertrauensarzt), who does not necessarily have to
be a specialist in the field [20]. If healthcare providers and
insurers do not agree on whether or not a treatment fulfils
the criteria of article 32 KVG, one of the two parties may
request the BAG to arrange a discussion and propose an
adjustment in the KLV, or the insured person can have a re-
jected application for reimbursement of costs reviewed by
a court. For example, the insurance court of the Canton St
Gallen issued a judgment on LVA in 2017 and concluded
that the few studies available at that time could not prove
the effectiveness of the procedure with significant proba-
bility [21]. In contrast, in November 2018, after a patient-
initiated complaint, the cantonal court of Vaud decided that
microsurgical LTT in a lymphoedema patient had to be
paid for retrospectively by the health insurance company
[22]. At that time, the method had been described as ef-
fective, appropriate and economical. We did not analyse
the economic aspects of lymphatic surgery in particular,
but would encourage such investigations by independent
researchers. For instance, Canadian authors recently com-
pared the economic impact of complex decongestive ther-
apy and LVA in the management of upper extremity lym-
phoedema and concluded that, in their country,
lymphoedema has substantial ongoing costs irrespective of
the treatment modality [23].
On the basis of this and since the use of lymphatic re-
constructive surgery for the treatment of lymphoedema is
officially not reimbursed by the Swiss healthcare system
at this point of time, an approval rate of 67% in Canton
Zurich from 2017 to 2020 suggests that most payers have
either accepted the current level of evidence for recon-
structive microsurgical therapies in lymphoedema patients
or act solely on the principle of trust. Negative or positive
criteria lists are not established so far. On the other hand,
one third of all appeals were refused, which proves that
payers still decide about coverage of lymphatic micro-
surgery on an individual basis. The frequency of refusal
of coverage varies widely among insurers. It is striking
that some insurers approved whereas others refused all of
our requests for reimbursement. These numbers also reveal
that insurance coverage continues to be a barrier to patient
access for these innovative and promising therapies, since
clinical criteria common to all 15 cases finally refused
could not be identified. In fact, reimbursement of costs was
refused independently of lymphoedema severity without
reasonable explanations. We did not identify case-related
patterns in the decision making either of individual health
insurers or between different insurers when we compared
the approved and refused cases. In addition, there was a
lack of correlation with lymphoedema severity. Decisions
currently seem to depend on individual insurers rather than
on the patients’ individual lymphoedema characteristics or
therapies already used. We further believe that there should
be no difference in approving costs for patients with pri-
mary or secondary lymphoedema, which was not the case
in our patient population: 88% of primary lymphoedema
cases and 66% of secondary lymphoedema cases were ap-
proved for coverage. Most of our requests for reimburse-
ment were approved in the first half of 2020, which might
illustrate a rather positive trend. However, reimbursement
rates per year varied around 70% per year from 2017–2020
and were more or less similar over the study period.
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We identified nine different insurance companies. No in-
surance company provided established policies for deci-
sion making on cost coverage, and insurers allegedly de-
cide on a case-by-case basis when provided with certain
patient details. However, based on our data health insurers
seem to make their decision for reimbursement of costs
based upon subjective criteria.
The results show that the process of reimbursement re-
quested by the surgeon significantly delays patients’ access
to adequate treatment by 50 days on average. Requests
consume immense office resources and yet can ultimately
result in rejection of the claim and frustration for physi-
cians and patients alike. This can be avoided if medical
necessity criteria are predefined. A streamlined reimburse-
ment process would eliminate delays for patients and re-
duce burdens for both providers and payers. Our results
may not be valid for every single canton or local healthcare
system in Switzerland, but are most probably representa-
tive for Switzerland. These findings highlight a need for in-
creased efficiency, transparency and collaboration among
policymakers, payers and physicians to promote patient
care and research. It might be helpful for policymakers
and health insurers to discuss the Austrian and German de-
velopments and eventually define medical necessity crite-
ria, as well as establish transparent policies. Our findings
reveal a potential opportunity to adjust current practices
in Switzerland and should support future discussions and
decisions. In addition, raising public awareness of lym-
phedema and new therapeutic strategies in the framework
of Swiss legislation and in close agreement with societies
representing lymphoedema patients might further promote
reconstructive microsurgical lymphoedema therapy in
Switzerland in the future.
Objective clinical results turn out to be not simple to deter-
mine in lymphoedema patients and there is an urgent need
for larger scale comparative and randomised controlled tri-
als to support decision making. However, the primary goal
for some patients is, for example, not always solely re-
duction of limb volume or circumference. Slowing down
or stopping the progression of the disease, reducing the
class of compression stockings and subjective discomfort
such as heaviness and pressure sensation are often desir-
able postoperative results. Given the current difficulties in
the standardised assessment of objective outcomes after
microsurgical therapies for lymphoedema, investigations
into alternative measures, such as standardised patient re-
ported outcome measurements, will help to establish a fur-
ther understanding of the benefits [24, 25].
Conclusion
In conclusion, 67% of reconstructive microsurgical opera-
tions for lymphoedema were ultimately approved by health
insurers, although the treatment is officially not reimbursed
by the Swiss healthcare system at this point in time. De-
cisions regarding reimbursement of lymphatic surgery ap-
pear to be rather uniform within the respective insurance
company and not always based on the individual case.
These results elaborated in the canton of Zurich may not
be valid for every single canton or local healthcare system
in Switzerland, but are most probably representative for
Switzerland. Large scale randomised controlled trials that
compare conservative therapy to lymphatic microsurgery
objectively should be conducted and investigations on al-
ternative tools such as patient reported outcome measure-
ments should be generated to provide further supportive
evidence for decision making in the future.
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